RemeGen Co., Ltd. announce that telitacicept, the dual targeted TACI-Fc fusion protein independently developed in-house by the Company, has been granted conditional marketing approval by the National Medical Products Administration of the People's Republic of China for the treatment of patients with Systemic Lupus Erythematosus (SLE). The grant of marketing approval for telitacicept is a significant accomplishment of the Group. It signifies the Group's achievements in the field of autoimmune diseases. It also demonstrates the Group's ability to develop biologic drugs and reflects the Group's strong in-house research and development capabilities. SLE has one of the higher mortality and disability rates among autoimmune rheumatic diseases. According to Frost & Sullivan, the global SLE prevalence was approximately 7.7 million in 2019, and it is estimated to reach 8.6 million by 2030. In China, there were approximately 1.0 million SLE patients in 2019, which is estimated to grow to approximately 1.1 million by 2030. According to Frost & Sullivan, the market size of global SLE biological therapeutics is estimated to grow at a CAGR of 26.8% from USD 0.8 billion in 2019 to USD 10.8 billion by 2030. Telitacicept is the second innovative biologics drug approved to treat SLE in China over the past 60 years.